Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness

Abstract Introduction The significantly greater cost of proton therapy compared with X‐ray therapy is frequently justified by the expected reduction in normal tissue toxicity. This is often true for indications such as paediatric and skull base cancers. However, the benefit is less clear for other m...

Full description

Bibliographic Details
Main Authors: Annabelle M. Austin, Michael J.J. Douglass, Giang T. Nguyen, Lisa Cunningham, Hien Le, Yvonne Hu, Scott N. Penfold
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Journal of Medical Radiation Sciences
Subjects:
Online Access:https://doi.org/10.1002/jmrs.416
_version_ 1818928495403728896
author Annabelle M. Austin
Michael J.J. Douglass
Giang T. Nguyen
Lisa Cunningham
Hien Le
Yvonne Hu
Scott N. Penfold
author_facet Annabelle M. Austin
Michael J.J. Douglass
Giang T. Nguyen
Lisa Cunningham
Hien Le
Yvonne Hu
Scott N. Penfold
author_sort Annabelle M. Austin
collection DOAJ
description Abstract Introduction The significantly greater cost of proton therapy compared with X‐ray therapy is frequently justified by the expected reduction in normal tissue toxicity. This is often true for indications such as paediatric and skull base cancers. However, the benefit is less clear for other more common indications such as breast cancer, and it is possible that the degree of benefit may vary widely between these patients. The aim of this work was to demonstrate a method of individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness of treatment. Methods 16 left‐sided breast cancer patients had a treatment plan generated for the delivery of intensity‐modulated proton therapy (IMPT) and of intensity‐modulated photon therapy (IMRT) with the deep inspiration breath‐hold (DIBH) technique. The resulting dosimetric data was used to predict probabilities of tumour control and toxicities for each patient. These probabilities were used in a Markov model to predict costs and the number of quality‐adjusted life years expected as a result of each of the two treatments. Results IMPT was not cost‐effective for the majority of patients but was cost‐effective where there was a greater risk reduction of second malignancies with IMPT. Conclusion The Markov model predicted that IMPT with DIBH was only cost‐effective for selected left‐sided breast cancer patients where IMRT resulted in a significantly greater dose to normal tissue. The presented model may serve as a means of evaluating the cost‐effectiveness of IMPT on an individual patient basis.
first_indexed 2024-12-20T03:29:49Z
format Article
id doaj.art-f88f2a6881cd4940b4845d5d9cc9418b
institution Directory Open Access Journal
issn 2051-3895
2051-3909
language English
last_indexed 2024-12-20T03:29:49Z
publishDate 2021-03-01
publisher Wiley
record_format Article
series Journal of Medical Radiation Sciences
spelling doaj.art-f88f2a6881cd4940b4845d5d9cc9418b2022-12-21T19:55:01ZengWileyJournal of Medical Radiation Sciences2051-38952051-39092021-03-01681445110.1002/jmrs.416Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectivenessAnnabelle M. Austin0Michael J.J. Douglass1Giang T. Nguyen2Lisa Cunningham3Hien Le4Yvonne Hu5Scott N. Penfold6Department of Physics University of Adelaide Adelaide SA AustraliaDepartment of Physics University of Adelaide Adelaide SA AustraliaSchool of Mathematical Sciences University of Adelaide Adelaide SA AustraliaDepartment of Radiation Oncology Royal Adelaide Hospital Adelaide SA AustraliaDepartment of Radiation Oncology Royal Adelaide Hospital Adelaide SA AustraliaDepartment of Radiation Oncology Royal Adelaide Hospital Adelaide SA AustraliaDepartment of Physics University of Adelaide Adelaide SA AustraliaAbstract Introduction The significantly greater cost of proton therapy compared with X‐ray therapy is frequently justified by the expected reduction in normal tissue toxicity. This is often true for indications such as paediatric and skull base cancers. However, the benefit is less clear for other more common indications such as breast cancer, and it is possible that the degree of benefit may vary widely between these patients. The aim of this work was to demonstrate a method of individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness of treatment. Methods 16 left‐sided breast cancer patients had a treatment plan generated for the delivery of intensity‐modulated proton therapy (IMPT) and of intensity‐modulated photon therapy (IMRT) with the deep inspiration breath‐hold (DIBH) technique. The resulting dosimetric data was used to predict probabilities of tumour control and toxicities for each patient. These probabilities were used in a Markov model to predict costs and the number of quality‐adjusted life years expected as a result of each of the two treatments. Results IMPT was not cost‐effective for the majority of patients but was cost‐effective where there was a greater risk reduction of second malignancies with IMPT. Conclusion The Markov model predicted that IMPT with DIBH was only cost‐effective for selected left‐sided breast cancer patients where IMRT resulted in a significantly greater dose to normal tissue. The presented model may serve as a means of evaluating the cost‐effectiveness of IMPT on an individual patient basis.https://doi.org/10.1002/jmrs.416breast cancercost‐effectivenessMarkov modelproton therapyradiobiological models
spellingShingle Annabelle M. Austin
Michael J.J. Douglass
Giang T. Nguyen
Lisa Cunningham
Hien Le
Yvonne Hu
Scott N. Penfold
Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
Journal of Medical Radiation Sciences
breast cancer
cost‐effectiveness
Markov model
proton therapy
radiobiological models
title Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
title_full Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
title_fullStr Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
title_full_unstemmed Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
title_short Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness
title_sort individualised selection of left sided breast cancer patients for proton therapy based on cost effectiveness
topic breast cancer
cost‐effectiveness
Markov model
proton therapy
radiobiological models
url https://doi.org/10.1002/jmrs.416
work_keys_str_mv AT annabellemaustin individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT michaeljjdouglass individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT giangtnguyen individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT lisacunningham individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT hienle individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT yvonnehu individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness
AT scottnpenfold individualisedselectionofleftsidedbreastcancerpatientsforprotontherapybasedoncosteffectiveness